「de」の検索結果
168件：16～20件目を表示
-
1回1滴で、充血クリアｌマイティアルミファイｌ千寿製薬
日目の結膜充血スコアの推移 （平均値 ± 標準誤差）（Full Analysis Set） ※Use of the ORA Calibra Redness/Hyperemia Scale was made under license from Ora,Inc 安全性 ＋ ー 安全性評価において、副作用として本品群109人中1人（0.9%）に軽度の眼圧低下が認められましたが、発現後も本品の投与は継続...
https://www.senju.co.jp/consumer/mytearlumify -
ting Approval for “ Mytear LUMIFY” Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida) today announces that it has received approval for the marketing of “Mytear...
https://www.senju.co.jp/system/files/content_news/2024-08/ENG_20240903.pdf -
ry Eye Disease treatment, SJP-0132 Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter: Senju) is developing a compound (development code: SJP-0132) ...
https://www.senju.co.jp/system/files/content_news/2024-07/ENG_20240716_0.pdf -
n of Software for Dry-eye Analysis Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces the launch of distribution of softwa...
https://www.senju.co.jp/system/files/content_news/2024-09/ENG_20240906.pdf -
ting Approval for “ Mytear LUMIFY” Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida) today announces that it has received approval for the marketing of “Mytear...
https://www.senju.co.jp/system/files/content_news/2024-08/ENG_20240903_0.pdf